Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis

NCT06141473 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06141473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06141473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 13, 2023
Completion date
May 6, 2027
Enrollment
1,655 (actual)
Sites
382

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis